

SAT KARTAR LIFE LIMITED

(Formerly known as Sat Kartar Shopping Limited)



Dated: 05.05.2026

To,
The Manager- Listing Compliance
National Stock Exchange India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla complex, Bandra (E),
Mumbai 400051

SYMBOL: SATKARTAR
ISIN: INE0NB801022

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 related to Press Release.

Dear Sir/Ma'am

Pursuant to Regulation 30 of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, please find enclosed a Press Release issued by the Company on the Financial Results of the Company for the financial year ended on March 31, 2026.

You are requested to kindly take the said information on your record and acknowledge it.

Thanking you,
Yours faithfully,
For Sat Kartar Life Limited
(Formerly known as Sat Kartar Shopping Limited)

Sonal Digitally signed
by Sonal Seth
Seth Date: 2026.05.05
18:35:04 +05'30'

Sonal Seth
Company Secretary & Compliance Officer
Membership No. F13949
Date: 05.05.2026
Place: New Delhi

Regd Office: 603, 6th Floor, Mercantile House, KG Marg, New Delhi -110001
Tel No. +011-40550741, website: www.satkartar.in, Email id: info@satkartar.in

CIN: L52590DL2012PLC238241



PRESS RELEASE

Sat Kartar Life Reports Strong FY26 Performance

Enters Next Phase of Growth

New Delhi, 5th May, 2026- Sat Kartar Life Ltd (NSE:SME- SATKARTAR), a listed company in the Ayurvedic Healthcare and Wellness segment, reported a **strong financial performance for the half year and full year ended March 31, 2026**, supported by rising consumer demand for natural healthcare solutions and continued focus on brand building and distribution expansion.

Financial Summary: Consolidated (In ₹Cr.)

Particulars	H2FY26	H2FY25	YoY(%)	FY26	FY25	YoY(%)
Revenue	110.62	87.13	26.96	200.70	162.92	23.19
EBITDA	14.87	8.60	72.91	24.69	14.23	73.51
EBITDA %	13.44	9.87	357 bps	12.30	8.73	357 bps
PAT	9.80	5.99	63.61	17.10	9.81	74.31
PAT %	8.86	6.88	198 bps	8.52	6.00	252 bps
EPS	6.22	4.50	38.22	10.86	7.37	47.35

Key Financial Highlights:

- **Consolidated Revenue:** ₹110.62 Cr in H2FY26 (+26.96% YoY) and ₹200.70 Cr in FY26 (+23.19% YoY).
- **EBITDA & Margins:** EBITDA at ₹14.87 Cr in H2FY26 (+72.91% YoY) with margin of 13.44% (+357 bps); ₹24.69 Cr in FY26 (+73.51% YoY) with margin of 12.30% (+357 bps).
- **PAT & Margins:** PAT at ₹9.80 Cr in H2FY26 (+63.61% YoY) with margin of 8.86% (+198 bps); ₹17.10 Cr in FY26 (+74.31% YoY) with margin of 8.52% (+252 bps).



Major Business Achievements

- Initiated operations of its **first 30-bed Ayurveda hospital** in Delhi.
- **₹48.58 Cr fundraise** led by institutional investors and HNIs, supporting healthcare expansion and strategic initiatives.
- Strategic **MoU with Jeena Sikho Lifecare Ltd** to build a scalable Ayurveda healthcare ecosystem.

Future Outlook

- The Company remains confident of achieving, and potentially surpassing, its medium-term **revenue target of ₹500 crore by FY28**, driven by its dual-engine growth model.
- Hospital capacity expansion: **30 → 300 beds (FY27)**.
- Expected **₹100+ Cr revenue contribution from hospitals** by FY28.
- Expansion into **global markets (US)** and high-margin nutraceutical segments.

Management Commentary

Speaking on the performance and growth outlook, Mr. Manprit Singh Chadha, Founder and Chief Operating Officer, said, *“As we move through the second half of FY26, Sat Kartar Life Ltd. has entered a pivotal phase in its growth journey. The launch of our first Sat Kartar Ayurveda Hospital marks our expansion of the business into an integrated Ayurveda healthcare enterprise, combining products, clinical care, and data-driven insights into a patient-centric ecosystem. Our collaboration with Jeena Sikho Lifecare Ltd. is accelerating this vision, as we build a scalable institutional platform with modern infrastructure and standardized protocols. Encouraged by early traction, we are focused on expanding our footprint and remain confident of reaching 300 beds by FY27. Our products business continues to perform strongly, supported by an expanding portfolio, improved efficiencies, and deeper market reach through our multilingual salesforce. The integration of medical expertise is further enhancing trust and customer value. Our AI initiatives are directly linked to measurable outcomes including improved conversion rates, reduced customer acquisition cost (CAC), and enhanced agent productivity ensuring that AI investments translate into tangible business returns, not just experimentation. With international expansion underway, we are well-positioned to strengthen our global presence. We remain confident in achieving our ₹500 Crore revenue milestone by FY28, driven by our dual-engine model, innovation, and strategic partnerships, while maintaining a strong focus on profitability and long-term value creation.”*



Earnings Call Details

Date	Thursday, May 7th 2026
Time	04:00pm IST
Call Leader	Nuvama Wealth PCG
Registration Link	<u>LINK</u>
Meeting ID/Pass	820 6033 6549 / 775911

About Sat Kartar Life Limited:

Sat Kartar Life Limited is a technology-enabled Ayurveda healthcare company focused on therapeutic and lifestyle solutions. The Company operates a scalable digital-first model supported by a multilingual customer engagement platform and is expanding into integrated healthcare delivery through Ayurveda hospitals. We integrate traditional Ayurvedic knowledge with modern research to empower individuals to adopt healthier lifestyles. With a strong market presence and a diverse product portfolio, we focus on innovation and responsive product development and establishing ourselves as a dedicated player in this sector and emphasizing quality and effectiveness in our holistic wellness offerings.

Our website- www.satkartar.co.in

For more information, contact:

Sat Kartar Life Ltd

Ms. Sonal Seth

Company Secretary and Compliance Officer

Email: info@satkartar.in

Merlin Capital Advisors

Mr. Ayush Divecha

Contact: +91 81048 55515

Email: ir@merlincapital.co.in

* * *